VG H&N course intro Florence 2016.pptx

Previous Page

Next Page

Page Background

On-going validation studies

IAEA-HypoX

•

Randomized phase III; accelerated radiotherapy

± Nimorazole

–

hypoxia gene expression and HPV/p16

–

Eastern Europe, Asia

–

Recruitment opened 2012

Intergroup EORTC - ROG HNCG 1219

DAHANCA

•

Randomized phase III; accelerated

chemoradiotherapy ± Nimorazole

–

hypoxia gene expression and HPV/p16

–

Europe, Canada

–

Recruitment starting 2013